Sign in
TerminatedNo phase

Retrospective Study on the Safety of Nivolumab in Patients With mRCC and Renal Failure

Key facts

Who runs it
Azienda USL Reggio Emilia - IRCCS
Where
Italy1 site in 1 countryChoose a country to see its sites
Trial code
Status
Terminated
People taking part
81 people enrolled
Started
29 Jun 2020
Ended
30 Jun 2025
Type of study
Observational, 3 groups
Record updated
11 September 2025
Why it stopped
Healted Prematurely

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (6)Hide the full registry criteria

Who can take part

  • signing informed consent, in case of patients still alive
  • histologically confirmed diagnosis of metastatic renal cell carcinoma
  • at least one administration of Nivolumab therapy, in the second-or third line of treatment february 2017 to December 31, 2018
  • availability of inpatient and/or outpatient medical records for clinical data collection

Who cannot take part

  • patients who have received immunotherapy under EAP (Expanded Access Programm) or other clinical trials
  • dialysis patients

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This is an observational, retrospective, multicenter study aimed to compare the toxicity of Nivolumab in patients with metastatic renal cell carcinoma treated in line II and III stratified into 3 patient groups:

Read full original descriptionShow less

* patients with normal or mildly reduced renal function (GFR<90 and ≥60 ml/min/1.73 m\^2); * patients with moderate renal impairment (GFR <60 e ≥30 ml/min/1.73 m\^2), * patients with severe renal impairment (GFR <30 e ≥15 ml/min/1.73 m\^2) Patients must have been treated with Nivolumab, as per clinical practice. All patients who have received at least one drug administration between february 2017 to December 31, 2018 will be enrolled in the study.

The 3 groups in the trial

  • Patients with normal or mildly reduced renal function (GFR<90 and ≥60 ml/min/1.73 m^2)
  • Patients with moderate renal failure (GFR <60 e ≥30 ml/min/1.73 m^2)
  • Patients with severe renal failure (GFR <30 e ≥15 ml/min/1.73 m^2)

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Retrospective Observational Study on the Safety of Nivolumab in Patients With Metastatic Renal Carcinoma and Renal Failure
Record updated
11 September 2025